PACS Group (NYSE:PACS) and COMPASS Pathways (NASDAQ:CMPS) Critical Survey

COMPASS Pathways (NASDAQ:CMPS) and PACS Group (NYSE:PACS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.

Insider & Institutional Ownership

46.2% of COMPASS Pathways shares are owned by institutional investors. 3.9% of COMPASS Pathways shares are owned by insiders. Comparatively, 70.4% of PACS Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

COMPASS Pathways has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, PACS Group has a beta of -0.65, indicating that its stock price is 165% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for COMPASS Pathways and PACS Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
COMPASS Pathways	1	1	7	0	2.67
PACS Group	0	2	3	0	2.60

COMPASS Pathways presently has a consensus price target of $16.25, suggesting a potential upside of 146.59%. PACS Group has a consensus price target of $43.25, suggesting a potential upside of 17.56%. Given COMPASS Pathways’ stronger consensus rating and higher possible upside, research analysts plainly believe COMPASS Pathways is more favorable than PACS Group.

Profitability

This table compares COMPASS Pathways and PACS Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
COMPASS Pathways	N/A	-111.18%	-56.55%
PACS Group	3.29%	21.39%	3.09%

Earnings & Valuation

This table compares COMPASS Pathways and PACS Group”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
COMPASS Pathways	N/A	N/A	-$155.12 million	($2.72)	-2.42
PACS Group	$4.09 billion	1.41	$55.76 million	$1.05	35.04

PACS Group has higher revenue and earnings than COMPASS Pathways. COMPASS Pathways is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Summary

PACS Group beats COMPASS Pathways on 8 of the 13 factors compared between the two stocks.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

About PACS Group

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.